New hope for advanced breast cancer: experimental drug JSKN003 faces off against standard care
NCT ID NCT07545044
First seen Apr 23, 2026 · Last updated Apr 24, 2026 · Updated 1 time
Summary
This study tests a new drug called JSKN003 against the usual treatment for HER2-positive breast cancer that has returned or spread. About 60 adults who have not had prior therapy for advanced disease will be randomly assigned to receive either JSKN003 or a combination of trastuzumab, pertuzumab, and docetaxel. The main goal is to see if JSKN003 shrinks tumors better, while also monitoring side effects and how long the benefit lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE RECURRENT OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.